NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald reiterated its Overweight rating and $16 price target on NeuroPace (NPCE) following a positive physician survey regarding the company's RNS System and its potential FDA approval for idiopathic generalized epilepsy (IGE). The survey reinforced confidence in FDA approval, with physicians viewing NAUTILUS data favorably; this comes as NeuroPace reported a 22% year-over-year sales increase, with full year 2024 revenue reaching $79.9 million. NPCE recently secured a $75 million credit facility and has received Buy ratings from H.C. Wainwright and UBS, both with an $18 price target.

Analysis

Cantor Fitzgerald's reaffirmation of an Overweight rating and a $16.00 price target on NeuroPace (NPCE) stems from a positive survey of 30 medical professionals, which bolstered confidence in the potential FDA approval of its RNS System for idiopathic generalized epilepsy (IGE). Despite the NAUTILUS study not meeting its primary endpoint, surveyed physicians predominantly viewed its data favorably and anticipate an expanded indication for the neurostimulation device. This potential regulatory milestone is significant for NeuroPace, which has demonstrated robust financial health with a 22% year-over-year revenue increase, achieving $79.9 million in sales for the full year 2024, and has seen its stock surge over 71% in the past year. Investor confidence is further supported by a recently secured $75 million credit facility aimed at enhancing patient access and funding growth. The broader analyst sentiment is similarly bullish, with H.C. Wainwright initiating coverage with a Buy rating and an $18 price target, and UBS reiterating a Buy rating also with an $18 target, reflecting targets that suggest considerable upside from NeuroPace's current $363 million valuation.

Key Decisions for Investors

• Investors may consider the current positive analyst sentiment and strong revenue growth as indicators of potential continued upside for NeuroPace, especially given price targets suggesting significant room from current levels.
• Monitoring the progress and outcome of the FDA's review for the RNS System's expanded IGE indication is crucial, as approval would likely be a significant catalyst for the stock and validation of the optimistic physician survey.
• While the outlook is optimistic, investors should remain cognizant of the risks associated with regulatory outcomes, as highlighted by the NAUTILUS study's primary endpoint miss, and the company's ability to successfully commercialize and drive adoption for any new indications.